Table 2.
Cox regression models on overall survival and progression-free survival
| Overall survival | Progression-free survival | |||
|---|---|---|---|---|
| Factors | Univariate HR, 95% CI, P-value | Multivariate HR, 95% CI, P-value | Univariate HR, 95% CI, P-value | Multivariate HR, 95% CI, P-value |
| Sex (M vs F) | 1.71 (0.96–3.05), P = 0.07 | 1.35 (0.82–2.21) P = 0.24 | ||
| Age (years) | 1.00 (0.98–1.02), P = 0.72 | 1.00 (0.98–1.01) P = 0.74 | ||
| Lines of treatment: | P = 0.55 | P = 0.63 | ||
| 2 vs 1 | 1.23 (0.57–2.64) | 1.06 (0.56–1.99) | ||
| ≥ 3 vs 1 | 1.56 (0.69–3.55) | 1.35 (0.67–2.73) | ||
| BRAF (mutant vs wild-type) | 1.14 (0.64–2.04), P = 0.65 | 1.32 (0.80–2.19) P = 0.28 | ||
| Brain metastases (yes vs no) | 1.03 (0.56–1.87), P = 0.93 | 1.30 (0.77–2.18) P = 0.32 | ||
| Lactate dehydrogenase (≥454 vs < 454) | 3.06 (1.69–5.57), P < 0.0001 | 2.51 (1.36–4.64), P = 0.003 | 2.16 (1.18–3.99) P = 0.01 | 1.74 (1.03–2.94) P = 0.04 |
| Absolute neutrophil count (≥5.4 vs < 5.4) | 2.04 (1.17–3.57), P = 0.01 | 1.60 (0.98–2.61) P = 0.06 | ||
| White blood cell count (≥7.6 vs < 7.6) | 1.57 (0.91–2.73), P = 0.11 | 1.55 (0.95–2.54) P = 0.08 | ||
| Neutrophil-to-lymphocyte ratio (≥5.0 vs < 5.0) | 3.53 (2.02–6.16), P < 0.0001 | 2.85 (1.60–5.08), P < 0.0001 | 2.53 (1.53–4.18) P < 0.0001 | 2.10 (1.23–3.59) P = 0.007 |
| Derived neutrophil-to-lymphocyte ratio (≥3.0 vs < 3.0) | 2.70 (1.55–4.69), P < 0.0001 | 2.50 (1.48–4.23) P = 0.001 | ||